Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Long-Term Investments (2021)

Aligos Therapeutics (ALGS) has disclosed Long-Term Investments for 1 consecutive years, with $15.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Investments changed N/A year-over-year to $15.1 million, compared with a TTM value of $15.1 million through Dec 2021, changed N/A, and an annual FY2021 reading of $15.1 million, changed N/A over the prior year.
  • Long-Term Investments was $15.1 million for Q4 2021 at Aligos Therapeutics, up from $492000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $15.1 million in Q4 2021 and bottomed at $492000.0 in Q3 2021.